Skip Nav Destination
Issues
15 October 2019
-
Cover Image
Cover Image
The cover shows a markup image (generated by the HALO image analysis software) for a clear-cell renal cell carcinoma section double immunostained for PD-L1 and markers of immune cells. PD-L1(+) immune cells are labeled in dark red and PD-L1(-) immune cells are labeled in light red. For details, see the article by Flaifel and colleagues on page 6080 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
Review
Clinical Trials: Targeted Therapy
Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation
Timothy Kinsella; Howard Safran; Susan Wiersma; Thomas DiPetrillo; Andrew Schumacher; Kayla Rosati; John Vatkevich; Lawrence W. Anderson; Kimberly D. Hill; Charles Kunos; Jerry M. Collins
Clinical Trials: Immunotherapy
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study
Suzanne Shusterman; Arlene Naranjo; Collin Van Ryn; Jaquelyn A. Hank; Marguerite T. Parisi; Barry L. Shulkin; Sabah Servaes; Wendy B. London; Hiroyuki Shimada; Jacek Gan; Steven D. Gillies; John M. Maris; Julie R. Park; Paul M. Sondel
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Anna V. Tinker; Holger W. Hirte; Diane Provencher; Marcus Butler; Heather Ritter; Dongsheng Tu; Hatem A. Azim, Jr; Paulo Paralejas; Nathalie Grenier; Shirley-Ann Hahn; Janelle Ramsahai; Lesley Seymour
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid; Luciana Molinero; Christopher R. Bolen; Jeffrey A. Sosman; Eva Muñoz-Couselo; Harriet M. Kluger; David F. McDermott; John D. Powderly; Indrani Sarkar; Marcus Ballinger; Marcella Fassò; Carol O'Hear; Daniel S. Chen; Priti S. Hegde; F. Stephen Hodi
Author Choice
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Frederick Lansigan; Cristiana A. Costa; Bassem I. Zaki; Stephanie P. Yen; Eric S. Winer; Helen Ryan; Darcie Findley; Sara R. Metzler; Lynn Shaw; Bonnie Toaso; Todd A. MacKenzie; Youdinghuan Chen; Anne W. Beaven
Precision Medicine and Imaging
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Abdallah Flaifel; Wanling Xie; David A. Braun; Miriam Ficial; Ziad Bakouny; Amin H. Nassar; Rebecca B. Jennings; Bernard Escudier; Daniel J. George; Robert J. Motzer; Michael J. Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J. Freeman; Toni K. Choueiri; Sabina Signoretti
Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study
Costanza Paoletti; Jieling Miao; Emily M. Dolce; Elizabeth P. Darga; Madeline I. Repollet; Gerald V. Doyle; Julie R. Gralow; Gabriel N. Hortobagyi; Jeffrey B. Smerage; William E. Barlow; Daniel F. Hayes
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu; Maneka Puligandla; Judith Manola; Andrea J. Bullock; Daniel Tamasauskas; David F. McDermott; Michael B. Atkins; Naomi B. Haas; Keith Flaherty; Robert G. Uzzo; Janice P. Dutcher; Robert S. DiPaola; Rupal S. Bhatt
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Ahmed O. Kaseb; Nora S. Sánchez; Shiraj Sen; Robin K. Kelley; Benjamin Tan; Andrea G. Bocobo; Kian H. Lim; Reham Abdel-Wahab; Marc Uemura; Roberto Carmagnani Pestana; Wei Qiao; Lianchun Xiao; Jeffrey Morris; Hesham M. Amin; Manal M. Hassan; Asif Rashid; Kimberly C. Banks; Richard B. Lanman; AmirAli Talasaz; Kenna R. Mills-Shaw; Bhawana George; Abedul Haque; Kanwal P.S. Raghav; Robert A. Wolff; James C. Yao; Funda Meric-Bernstam; Sadakatsu Ikeda; Razelle Kurzrock
Translational Cancer Mechanisms and Therapy
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Siddhartha Devarakonda; Sumithra Sankararaman; Brett H. Herzog; Kathryn A. Gold; Saiama N. Waqar; Jeffrey P. Ward; Victoria M. Raymond; Richard B. Lanman; Aadel A. Chaudhuri; Taofeek K. Owonikoko; Bob T. Li; John T. Poirier; Charles M. Rudin; Ramaswamy Govindan; Daniel Morgensztern
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar; Bose S. Kochupurakkal; Jean-Bernard Lazaro; Zhigang C. Wang; Sangeetha Palakurthi; Paul T. Kirschmeier; Chunyu Yang; Larissa A. Sambel; Anniina Färkkilä; Elizaveta Reznichenko; Hunter D. Reavis; Connor E. Dunn; Lee Zou; Khanh T. Do; Panagiotis A. Konstantinopoulos; Ursula A. Matulonis; Joyce F. Liu; Alan D. D'Andrea; Geoffrey I. Shapiro
Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model
In Ho Song; Mun Sik Jeong; Hyo Jeong Hong; Jong Il Shin; Yong Serk Park; Sang-Keun Woo; Byung Seok Moon; Kwang Il Kim; Yong Jin Lee; Joo Hyun Kang; Tae Sup Lee
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Megan Greally; Joanne F. Chou; Walid K. Chatila; Matthew Margolis; Marinela Capanu; Jaclyn F. Hechtman; Yaelle Tuvy; Ritika Kundra; Foysal Daian; Marc Ladanyi; David P. Kelsen; David H. Ilson; Michael F. Berger; Laura H. Tang; David B. Solit; Luis A. Diaz, Jr; Nikolaus Schultz; Yelena Y. Janjigian; Geoffrey Y. Ku
Author Choice
Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity
Yichen Chen; Jun Wang; Xi Wang; Xinye Li; Jingjing Song; Juan Fang; Xiangqi Liu; Tao Liu; Dikan Wang; Qunxing Li; Shuqiong Wen; Da Ma; Juan Xia; Liqun Luo; Song Guo Zheng; Jun Cui; Gucheng Zeng; Lieping Chen; Bin Cheng; Zhi Wang
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Laetitia Marzi; Ludmila Szabova; Melanie Gordon; Zoe Weaver Ohler; Shyam K. Sharan; Michael L. Beshiri; Moudjib Etemadi; Junko Murai; Kathleen Kelly; Yves Pommier
Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection
Kenji Tatsuno; Yutaka Midorikawa; Tadatoshi Takayama; Shogo Yamamoto; Genta Nagae; Mitsuhiko Moriyama; Hayato Nakagawa; Kazuhiko Koike; Kyoji Moriya; Hiroyuki Aburatani
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
Luca Lazzari; Giorgio Corti; Gabriele Picco; Claudio Isella; Monica Montone; Pamela Arcella; Erika Durinikova; Eugenia R. Zanella; Luca Novara; Fabiane Barbosa; Andrea Cassingena; Carlotta Cancelliere; Enzo Medico; Andrea Sartore-Bianchi; Salvatore Siena; Mathew J. Garnett; Andrea Bertotti; Livio Trusolino; Federica Di Nicolantonio; Michael Linnebacher; Alberto Bardelli; Sabrina Arena
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Fabienne Lucas; Kerry A. Rogers; Bonnie K. Harrington; Alexander Pan; Lianbo Yu; Justin Breitbach; Ralf Bundschuh; Virginia M. Goettl; Zachary A. Hing; Parviz Kanga; Rose Mantel; Deepa Sampath; Lisa L. Smith; Ronni Wasmuth; Danielle K. White; Pearlly Yan; John C. Byrd; Rosa Lapalombella; Jennifer A. Woyach
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds